Experimental cancer drug NEV801 enters first human tests
NCT ID NCT02797795
First seen May 14, 2026 · Last updated Jun 19, 2026 · Updated 7 times
Summary
This early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The study was completed, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Facility
Boston, Massachusetts, 02215, United States
-
Research Facility
Nashville, Tennessee, 37203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEV801 (an experimental drug given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or may cause side effects. Only 78 people took part, so results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.